About Acalabrutinib API
Categoría Terapéutica Oncology
Número CAS
870524-78-5
Tecnología del API
Molécula pequeña
Forma de Dosificación
Sólido Oral/Cápsulas
Estado de Desarrollo en Dr. Reddy’s
En desarrollo
Mechanism of Action
Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor. BTK is a protein that plays an important role in the survival and growth of B cells. By blocking BTK, acalabrutinib can help to slow down or even stop the growth of cancer cells.
Indication
The FDA approved Acalabrutinib for the treatment of adult patients with Mantle Cell Lymphoma (MCL) has received at least one prior therapy. Chronic lymphocytic leukemia (CLL). Small lymphocytic lymphoma (SLL).
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
Dasatinib
Oncology
Adagrasib
Oncology
Fruquintinib
Oncology
Tucatinib
Oncology
Ripretinib
Oncology
Bortezomib
Oncology
Cabazitaxel
Oncology
Cabozantinib HCl
Oncology
Cabozantinib S-Malate
Oncology
Capecitabina
Oncology
Carfilzomib
Oncology
Decitabina
Oncology
Deucravacitinib
Oncology
Mesilato De Eribulina
Oncology
Lomustina
Oncology
Nilotinib Clorhidrato
Oncology
Olaparib (Form A)
Oncology
Palbociclib
Oncology
Pazopanib
Oncology
Pemetrexed Disodium (Heptahidrato)
Oncology
Acalabrutinib
Oncology
Capivasertib
Oncology
Lenalidomida (Form A)
Oncology
Midostaurina(Amorphous and Form II)
Oncology
Lenvatinib Mesylate (Form C and MIBK Solvate)
Oncology
Enzalutamida (Crystalline & Premix)
Oncology
Pomalidomida
Oncology
Gemcitabine Hydrochloride
Oncology
Acetato De Abiraterona
Oncology
Apalutamide (Amorphous & Form B)
Oncology
Ácido Zoledrónico
Oncology
Venetoclax
Oncology
Azacitidina
Oncology
Clorhidrato De Bendamustina
Oncology
Relugolix
Oncology